Clinical trial · Observational
Bonefos and the Consumption of Analgesics
Bonefos and the Consumption of Analgesics. Influence of Clodronate on Analgesics Consumption Among Patients With Bone Metastasis
NCT00909142CI-TRIAL-00006677BICAMcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The effect of Bonefos on consumption of analgesics (drugs used for pain treatment) in patients with proven bone metastases.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bone Neoplasms | Bone Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bonefos (Clodronate, BAY94-8393) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Group1
- interventionNames
- Drug: Bonefos (Clodronate, BAY94-8393)
Primary outcomes (1)
- measure
- Analgesics consumption after 12 months of treatment with Bonefos in patients with bone metastases and breast or prostate cancer or multiple myeloma
- timeFrame
- 12 months
Secondary outcomes (1)
- measure
- Decrease in pain measured by VAS (Visual Analogue Scale)
- timeFrame
- 12 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Breast cancer or prostate cancer or multiple myeloma. * Bone metastasis. * Ability to use analgesics and clodronate 1600 mg/day. Exclusion Criteria: * Hypersensitivity to bisphosphonates. * Clodronate in previous therapy. * Concomitant use of other bisphosphonates. * Serious renal insufficiency.
References
Publications (0)
Data not yet available
No reference posted for this study.